Johnson & Johnson's RYBREVANT® Approved for New Dosing Options in EGFR-Mutated Lung Cancer

Key highlights
  • The European Commission approved subcutaneous dosing regimens for RYBREVANT® in advanced EGFR-mutated NSCLC.
  • The approval includes every-three-week and every-four-week dosing options.
  • Subcutaneous administration reduces clinic time to five minutes compared to five hours for intravenous infusion.
  • The approval is based on Phase 2 PALOMA-2 and Phase 1 PALOMA study results.

Approval Overview

The European Commission has approved new subcutaneous dosing regimens for RYBREVANT® (amivantamab) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). This includes every-three-week and every-four-week dosing options, expanding its use beyond the previously approved intravenous method.

Dosing Regimens

The every-four-week regimen is approved for use with LAZCLUZE® (lazertinib) for first-line treatment of adult patients with specific EGFR mutations. The every-three-week regimen is approved in combination with carboplatin and pemetrexed for patients with advanced NSCLC after failure of prior therapy.

Clinical Benefits

Subcutaneous administration offers practical advantages, such as reduced clinic time, with administration taking approximately five minutes compared to five hours for intravenous infusion. It also results in fewer administration-related reactions, maintaining efficacy and safety consistent with the intravenous formulation.

Supporting Studies

The approval is supported by data from the Phase 2 PALOMA-2 and Phase 1 PALOMA studies, which evaluated the feasibility, pharmacokinetics, efficacy, and safety of subcutaneous amivantamab. Results showed a response rate and safety profile consistent with historical intravenous dosing, with a significantly reduced incidence of administration-related reactions.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

5 November 2026
Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO in recurrent/metastatic HNSCC

Subcutaneous bispecific (amivantamab + hyaluronidase) approved for adults with recurrent/metastatic head and neck squamous cell carcinoma after platinum and anti‑PD‑(L)1 therapy.

11 September 2026
Johnson & Johnson: RYBREVANT OS and tolerability updates at WCLC 2026

Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.

30 July 2026
Johnson & Johnson: FDA Priority Review for potential first-in-class subcutaneous RYBREVANT FASPRO in recurrent/metastatic HNSCC

OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.

31 May 2026
Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.

25 October 2026
Johnson & Johnson: RYBREVANT FASPRO shows high response in first‑line advanced head and neck cancer

Cohort 5 reported 77% confirmed ORR (14% CR) in non‑HPV HNSCC with subcutaneous amivantamab + pembrolizumab and carboplatin; median follow‑up 10.6 months; safety consistent with known profiles.